Ocriplasmin
- Generic Name
- Ocriplasmin
- Brand Names
- Jetrea
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1048016-09-6
- Unique Ingredient Identifier
- 7V6HE3DM5A
- Background
Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.
- Indication
Ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.
- Associated Conditions
- Symptomatic Vitreomacular Adhesion (VMA)
- Associated Therapies
- -
A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 60
- Registration Number
- NCT00435539
- Locations
- 🇧🇪
ZNA OCMW Antwerpen, Antwerpen, Belgium
🇧🇪University Hospital of Ghent, Ghent, Belgium
🇧🇪Universitaire Ziekenhuizen K.U.Leuven, Leuven, Belgium
Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVT
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 6
- Registration Number
- NCT00428129
- Locations
- 🇮🇪
Section of Interventional Radiology, Department of Radiology, University College Hospital, Newcastle Road, Galway, Co Galway, Ireland
A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 51
- Registration Number
- NCT00412451
- Locations
- 🇪🇸
Instituto Technologico de Oftalmologia SL., Santiago de Compostela, Spain
🇳🇱Academic Hospital Groningen, Groningen, Netherlands
🇳🇱Het Oogziekenhuis Rotterdam, Rotterdam, Netherlands
Intra-arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery Occlusion
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 2
- Registration Number
- NCT00123266
- Locations
- 🇩🇪
Universitatsklinikum Freiburg, Freiburg, Germany
🇩🇪Universitätsklinikum Erlangen, Erlangen, Germany
🇩🇪HSK Dr. Horst Schmidt Hospital, Wiesbaden, Germany
Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 19
- Registration Number
- NCT00123292
- Locations
- 🇧🇪
University Hospital Gasthuisberg, Leuven, Belgium
Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy
- Conditions
- Interventions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 60
- Registration Number
- NCT00123279
- Locations
- 🇳🇱
Oogziekenhuis Rotterdam, Rotterdam, Netherlands
🇧🇪University Hospital Gasthuisberg, Leuven, Belgium
🇳🇱Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 40
- Registration Number
- NCT00123305
- Locations
- 🇦🇹
Allgemeines Offentliches Krankenhaus der, Linz, Austria
🇧🇪Cliniques Universitaires St Luc, Brussels, Belgium
🇦🇹Landesnervenklinik Wagner-Jauregg, Linz, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.